Fig. 3From: Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanomaFrequencies of CD4+CD25hiCD39+ Treg at baseline in healthy donors and patients. a Median levels of CD39+ Treg at baseline was lower in patients than in healthy donors, but the difference did not reach statistical significance (p = 0.144). b Median levels of CD39+ Treg at baseline was highest in healthy donors and lowest in non-relapsed patients, but the difference was not significantBack to article page